Zydus Lifesciences Ltd
NSE:ZYDUSLIFE

Watchlist Manager
Zydus Lifesciences Ltd Logo
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
Watchlist
Price: 844.4 INR -1.81% Market Closed
Market Cap: 849.7B INR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one ZYDUSLIFE stock under the Base Case scenario is hidden INR. Compared to the current market price of 844.4 INR, Zydus Lifesciences Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ZYDUSLIFE Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

3.8
P/S
P/S
Price to Sales
3.8
vs History
30
vs Industry
30
Median 3Y
3.4
Median 5Y
3.2
Industry
2.4
Forward
3.7
More Details
18.7
P/E
P/E
Price to Earnings
18.7
vs History
79
vs Industry
24
Median 3Y
22.6
Median 5Y
23.4
Industry
20.5
Forward
18.5
More Details
18.5
P/OCF
P/OCF
Price to OCF
18.5
vs History
49
vs Industry
22
Median 3Y
20.6
Median 5Y
18.7
Industry
15.4
More Details
26.7
P/FCFE
P/FCFE
Price to FCFE
26.7
vs History
55
vs Industry
17
Median 3Y
31.7
Median 5Y
28.5
Industry
22.8
More Details
3.9
P/B
P/B
Price to Book Value
3.9
vs History
36
vs Industry
17
Median 3Y
3.5
Median 5Y
3.5
Industry
1.9
More Details
3.7
EV/S
EV/S
Enterprise Value to Sales
3.7
vs History
31
vs Industry
30
Median 3Y
3.3
Median 5Y
3.2
Industry
2.5
Forward
3.6
More Details
5.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
5.1
vs History
39
vs Industry
36
Median 3Y
5.1
Median 5Y
5
Industry
4.9
More Details
13
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
13
vs History
69
vs Industry
26
Median 3Y
13.8
Median 5Y
14.1
Industry
12.4
Forward
12.1
More Details
15
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
15
vs History
82
vs Industry
26
Median 3Y
17
Median 5Y
17.5
Industry
15.5
Forward
13.9
More Details
17.9
EV/OCF
EV/OCF
Enterprise Value to OCF
17.9
vs History
61
vs Industry
23
Median 3Y
19.9
Median 5Y
18.8
Industry
14
More Details
25.8
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
25.8
vs History
69
vs Industry
18
Median 3Y
36.6
Median 5Y
29.6
Industry
17.9
More Details
3.1
EV/IC
EV/IC
Enterprise Value to IC
3.1
vs History
28
vs Industry
22
Median 3Y
2.8
Median 5Y
2.5
Industry
1.8
More Details

Multiples Across Competitors

ZYDUSLIFE Competitors Multiples
Zydus Lifesciences Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
849.7B INR 3.8 18.7 13 15
US
Eli Lilly and Co
NYSE:LLY
669.1B USD 15 64.1 36.9 40.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
356B USD 4 25.3 11.9 15.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK 6.3 18 11.9 13.6
CH
Roche Holding AG
SIX:ROG
193.7B CHF 3.3 16.8 9.5 11.3
CH
Novartis AG
SIX:NOVN
171.4B CHF 3.9 16.8 10.2 13.1
UK
AstraZeneca PLC
LSE:AZN
155.3B GBP 3.7 28.3 125.4 191.5
US
Merck & Co Inc
NYSE:MRK
195.2B USD 3 11.4 7.8 9.2
IE
Endo International PLC
LSE:0Y5F
162.4B USD 70 -55.5 259.5 650.8
US
Pfizer Inc
NYSE:PFE
122.1B USD 1.9 15.2 7.6 10.9
P/E Multiple
Earnings Growth PEG
IN
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
Average P/E: 23.9
18.7
5%
3.7
US
Eli Lilly and Co
NYSE:LLY
64.1
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
25.3
26%
1
DK
Novo Nordisk A/S
CSE:NOVO B
18
19%
0.9
CH
Roche Holding AG
SIX:ROG
16.8
16%
1.1
CH
Novartis AG
SIX:NOVN
16.8
16%
1
UK
AstraZeneca PLC
LSE:AZN
28.3
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.4
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -55.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
15.2
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
Average EV/EBITDA: 394.6
13
7%
1.9
US
Eli Lilly and Co
NYSE:LLY
36.9
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
11.9
7%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11.9
15%
0.8
CH
Roche Holding AG
SIX:ROG
9.5
8%
1.2
CH
Novartis AG
SIX:NOVN
10.2
5%
2
UK
AstraZeneca PLC
LSE:AZN
125.4
9%
13.9
US
Merck & Co Inc
NYSE:MRK
7.8
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
259.5
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
3%
2.5
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
Average EV/EBIT: 1 697.6
15
7%
2.1
US
Eli Lilly and Co
NYSE:LLY
40.7
33%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
15.6
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
13.6
16%
0.8
CH
Roche Holding AG
SIX:ROG
11.3
9%
1.3
CH
Novartis AG
SIX:NOVN
13.1
8%
1.6
UK
AstraZeneca PLC
LSE:AZN
191.5
21%
9.1
US
Merck & Co Inc
NYSE:MRK
9.2
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
650.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.9
10%
1.1

See Also

Summary
ZYDUSLIFE intrinsic value, competitors valuation, and company profile.
DCF Valuation
ZYDUSLIFE stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ZYDUSLIFE stock valuation using valuation multiples.
Wall Street Estimates
ZYDUSLIFE price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ZYDUSLIFE stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 245,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.